Simulations Plus Inc - Company Profile
Powered by 
All the sales intelligence you need on Simulations Plus Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Simulations Plus Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Simulations Plus Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Simulations Plus Inc (Simulations Plus) delivers advanced software and consulting services tailored for the biopharma industry. The company excels in expediting drug discovery, development, and commercialization through innovative, science-driven solutions. Its diverse product portfolio includes a range of software products for modeling, simulation, and data analysis, aiding clients in optimizing drug development processes, reducing costs, and enhancing regulatory compliance. Additionally, the company offers a comprehensive platform that spans the entire drug development value chain. The company provides adaptive learning solutions and medical communications services to support clinical trial success and post-regulatory commercialization. Simulations Plus is headquartered in Lancaster, California, in the US.
Headquarters
United States of America
Address
800 Park Offices Drive, Suite 401, Research Triangle Park, North Carolina, 27709
Website
www.simulations-plus.com
Telephone
1 661 7237723
No of Employees
212
Industry
Medical Equipment
Ticker Symbol & Exchange
SLP (NASD)
Revenue (2025)
$79.2M
13.1%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-750.2%
(2025 vs 2024)
Market Cap*
$228.9M
Net Profit Margin (2025)
XYZ
-674.8%
(2025 vs 2024)
* As of and is in US$
Simulations Plus Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| GastroPlus | Early Drug Discovery |
| MonolixSuite | Physiologically Based Pharmacokinetics (PBPK) |
| ADMET Predictor | Quantitative Systems Pharmacology (QSP) |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Research Grant | In November, the company received a newly funded grant from the US Food and Drug Administration (FDA) to use physiologically based pharmacokinetic (PBPK) approaches in GastroPlus to build and validate mechanistic in vitro-in vivo correlations (IVIVCs) for long-acting injectable (LAI) technologies through a joint proposal with the University of Connecticut’s School of Pharmacy, Department of Pharmaceutical Sciences. |
| 2024 | Research Grant | In October, the company received a newly funded grant from the US Food and Drug Administration (FDA), secured in partnership with the University of Strathclyde and InnoGI Technologies. |
| 2024 | Research Grant | In October, the company received a new research grant from the National Institutes of Health (NIH), secured in partnership with the University of Southern California (USC) Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences. |
Competitor Comparison
| Key Parameters | Simulations Plus Inc | ICON Plc | Veeva Systems Inc | Certara Inc | Schrodinger Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Ireland | United States of America | United States of America | United States of America |
| City | Research Triangle Park | Dublin | Pleasanton | Radnor | New York |
| State/Province | North Carolina | Dublin | California | Pennsylvania | New York |
| No. of Employees | 212 | 39,800 | 7,291 | 1,487 | 891 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dr. Daniel Weiner | Chairman | Executive Board | 2024 | 76 |
| Shawn O’Connor | Chief Executive Officer | Senior Management | 2018 | 67 |
| Will Frederick | Vice President; Chief Executive Officer; Secretary | Senior Management | 2020 | 63 |
| Josh Fohey | Chief Operating Officer | Senior Management | - | - |
| Jonathan Chauvin | Chief Technology Officer; Co-Chief Product Officer | Senior Management | 2025 | 44 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer